BIO vs ILMN

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Nov 10, 2026

BIO

59.1
AI Score
VS
BIO Wins

ILMN

57.8
AI Score

Investment Advisor Scores

BIO

Nov 10, 2026
59score
Recommendation
HOLD

ILMN

Nov 10, 2026
58score
Recommendation
BUY

AI Analyst Insights

Detailed Metrics Comparison

Metric BIO ILMN Winner
Forward P/E 41.6667 34.6021 ILMN
PEG Ratio 1.1905 2.6211 BIO
Revenue Growth 0.5% 4.2% ILMN
Earnings Growth 18.7% 45.9% ILMN
Tradestie Score 59.1/100 57.8/100 BIO
Profit Margin 39.5% 19.7% BIO
Beta 1.00 1.00 Tie
Implied Volatility N/A N/A Tie
AI Recommendation HOLD BUY ILMN

Relative Price Performance (Last 90 Days)

BIO 1M: +6.1% · 3M: +6.7% ILMN 1M: -22.3% · 3M: +11.4%

Current Technical Phase

BIO

Markup
Hold / add on dips

Price above SMA50, rising 50-day trend (0.6% over 20 days), RSI 58

RSI (14): 58.2 · Price: $386.48

ILMN

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 37

RSI (14): 37.3 · Price: $214.91

Fundamentals Snapshot

Metric BIO ILMN
Market Cap — —
Forward P/E 39.0 34.8
Trailing P/E 10.3 38.0
Revenue (TTM) — —
Revenue Growth 0.0% 0.0%
Gross Margin 0.5% 0.7%
Operating Margin 0.1% 0.2%
EPS 37.64 5.81
Dividend Yield — —

Frequently Asked Questions

Based on our detailed analysis, BIO is currently the stronger investment candidate, winning 3 of the key financial metrics based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.